Have a feature idea you'd love to see implemented?
Let us know!
BRNS Barinthus Biotherapeutics Plc.
Price (delayed)
$1.43
Market cap
$56.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
-$48.84M
vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed
Highlights
The debt is down by 3.1% YoY
The net income has contracted by 16% YoY but it has grown by 10% from the previous quarter
Barinthus Biotherapeutics's EPS has decreased by 14% YoY but it has increased by 10% from the previous quarter
BRNS's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of BRNS
Market
Valuations
Earnings
Shares outstanding
39.41M
Market cap
$56.36M
Enterprise value
-$48.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$65.21M
EBITDA
-$57.96M
Free cash flow
-$55.01M
Per share
Balance sheet
Liquidity
EPS
-$1.65
Free cash flow per share
-$1.41
Book value per share
$4.01
Revenue per share
$0
TBVPS
$3.87
Total assets
$186.75M
Total liabilities
$29.96M
Debt
$12.57M
Equity
$156.62M
Working capital
$116.29M
Debt to equity
0.08
Current ratio
8.46
Quick ratio
7.55
Net debt/EBITDA
1.82
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.7%
Return on equity
-35.9%
Return on invested capital
-209.8%
Return on capital employed
-38.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BRNS stock price
How has the Barinthus Biotherapeutics stock price performed over time
Intraday
4.38%
1 week
19.17%
1 month
19.17%
1 year
-54.46%
YTD
-61.25%
QTD
20.17%
Financial performance
How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.29M
Net income
-$63.79M
Gross margin
N/A
Net margin
N/A
BRNS's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
The net income has contracted by 16% YoY but it has grown by 10% from the previous quarter
BRNS's operating income is up by 10% from the previous quarter but it is down by 9% YoY
Growth
What is Barinthus Biotherapeutics's growth rate over time
Valuation
What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Barinthus Biotherapeutics's EPS has decreased by 14% YoY but it has increased by 10% from the previous quarter
The stock's price to book (P/B) is 40% less than its last 4 quarters average of 0.6
The equity has contracted by 16% YoY and by 9% from the previous quarter
BRNS's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Barinthus Biotherapeutics business performance
The return on equity has declined by 41% year-on-year but it has increased by 6% since the previous quarter
BRNS's return on assets is down by 36% year-on-year but it is up by 7% since the previous quarter
Barinthus Biotherapeutics's return on invested capital has decreased by 16% YoY but it has increased by 7% QoQ
Dividends
What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BRNS.
Financial health
How did Barinthus Biotherapeutics financials performed over time
Barinthus Biotherapeutics's quick ratio has decreased by 33% YoY and by 25% from the previous quarter
The current ratio fell by 32% YoY and by 24% QoQ
The debt is 92% lower than the equity
The equity has contracted by 16% YoY and by 9% from the previous quarter
BRNS's debt to equity is up by 14% since the previous quarter and by 14% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.